First Country in Europe Launches LATUDA® (lurasidone) - a New Atypical Antipsychotic for Adults with Schizophrenia (y 2)

Swiss launch marks the first step towards lurasidone becoming available across Europe

12. Chang C-K et al. Life Expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in London. PLoS One 2011;6:e19590.

13. Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res 2011;131:101-4.

14. Tiihonen J et al. 11 year-follow up of mortality in patients with scizophrenia: a population-based cohort study (FINN11 study). Lancet 2009;374:620-7.

15. Lewis DA and Lieberman JA. Neuron 2000;28:325-34.

16. Faries DE et al. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psych 2009;9:54.

17. Tsutsumi C et al. The evolution of antipsychotic switch and polypharmacy in natural practice - A longitudinal perspective. Schizophr Res 2011;130:40-6.

18. Salize HJ et al. Cost of schizophrenia in six European countries. Schizophr Res 2009;111(1-3):70-7.

19. Mangalore R and Knapp R. Cost of schizophrenia in England. J Ment Health Policy Econ 2007;10(1):23-41.

20. Zeidler J et al. The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective. Health Econ Rev 2012;2(1):9.

CONTACT: Media Enquiry Contacts: Kate Burd, Takeda PharmaceuticalsInternational GmbH, +44-7974-151510, Kate.burd@takeda.com ; Arran Attridge,Red Door Communications, +44-7812-398-525, aattridge@rdcomms.com